mrna-1645-coreg28v2
Nucleic acidexperimental
Clinical trial activity
1 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 19, 2025 (NCT06694753)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusINHIBITOR
Human immunodeficiency virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06694753 | Phase 1 | Feb 19, 2025 | Bill and Melinda Gates Foundation, HIV Vaccine Trials Network, International AIDS Vaccine Initiative, Moderna Therapeutics, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Perinatal HIV Research Unit, Baragwanath, Scripps, United States Agency for International Development |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 1 | 1 | 2025 |
| International AIDS Vaccine Initiative | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Moderna Therapeutics | For profit | 1 | 0 | 1 | 2025 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2025 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2025 |
| Perinatal HIV Research Unit, Baragwanath | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Scripps | Academic/Hospital | 1 | 0 | 1 | 2025 |
| United States Agency for International Development | Government | 1 | 0 | 1 | 2025 |
9 organizations
Page 1 / 1